Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Website: aerovatetx.com


  • Dividend yield for the last twelve months 89.6%
  • Free cash flow yield -122.3% (LTM)
  • Share price is 90.1% higher than minimum and 91.3% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 0.0x)

Key Financials (Download financials)

Ticker: AVTE
Share price, USD:  (0.0%)2.68
year average price 2.65  


year start price 2.45 2025-02-14

min close price 2.37 2025-02-18

max close price 2.77 2025-04-21

current price 2.68 2026-02-13
Common stocks: 28 985 019

Dividend Yield:  89.6%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):

Target EV / EBITDA (hist percentile): 0.0x
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 78
Net Debt ($m): -28
EV (Enterprise Value): 50
EBITDA LTM (млн $): -32
Price to Book: 0.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-04-07prnewswire.com

Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

2024-12-28businesswire.com

AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders

2024-11-05globenewswire.com

INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. – AVTE

2024-11-03prnewswire.com

INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. - AVTE

2024-11-01prnewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders

2024-10-31businesswire.com

Shareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

2024-06-20globenewswire.com

Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm

2024-06-18zacks.com

Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals

2024-06-17globenewswire.com

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

2024-05-21globenewswire.com

Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-14 2025-08-13 2024-11-12 2024-08-12 2024-05-13 2023-11-13 2023-08-14 2023-05-15 2022-11-14 2022-08-15
acceptedDate 2025-11-14 07:13:30 2025-08-13 16:20:41 2025-03-27 07:30:28 2024-11-12 16:40:34 2024-08-12 16:31:10 2024-05-13 16:57:50 2024-03-25 16:15:50 2023-11-13 08:16:11 2023-08-14 08:16:01 2023-05-15 16:11:52 2023-03-29 17:04:43 2022-11-14 07:50:45 2022-08-15 08:00:54 2022-03-30 16:51:14 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
costOfRevenue 0 0 0 0 28 000 28 000 96 000 25 000 22 000 0 68 000 0 0 0 1000
grossProfit 0 0 0 0 -28 000 -28 000 -96 000 -25 000 -22 000 0 -68 000 0 0 -15 000 -1000
grossProfitRatio 0 0 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 22M 23M 53M 10M 21M 20M 64M 17M 16M 13M 39M 11M 8M 15M 8M
generalAndAdministrativeExpenses 5M 5M 21M 7M 5M 5M 17M 4M 4M 4M 15M 3M 4M 8M 949 000
sellingAndMarketingExpenses 0 0 0 0 0 -28 000 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 5M 21M 7M 5M 5M 17M 4M 4M 4M 15M 3M 4M 8M 949 000
otherExpenses 0 0 0 0 0 -3000 0 1000 -1000 -1000 -79 000 0 0 -3000 0
operatingExpenses 27M 28M 75M 17M 26M 25M 81M 21M 20M 18M 53M 14M 12M 23M 9M
costAndExpenses 0 0 75M 17M 26M 25M 81M 21M 20M 18M 53M 14M 0 23M 9M
interestIncome 2M 2M 5M 1M 1M 1M 6M 2M 1M 1M 2M 560 000 230 000 65 000 75
interestExpense 0 0 0 0 0 0 0 0 0 -1M 0 560 000 0 65 000 75 000
depreciationAndAmortization 0 0 282 000 218 000 28 000 28 000 96 000 25 000 22 000 21 000 68 000 20 000 -4000 15 000 1000
ebitda -25M -28M -74M -17M -26M -25M -81M -21M -20M -18M -53M -14M -12M -23M -9M
ebitdaratio 0 0 0 0 0 0 0 0 0 0
operatingIncome -27M -28M -75M -17M -26M -25M -81M -21M -20M -18M -53M -14M -12M -23M -9M
operatingIncomeRatio 0 0 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet 2M -4M 5M 1M 1M 1M 6M 2M -1000 1M 2M 564 000 224 000 62 000 -722 000
incomeBeforeTax -25M -32M -70M -16M -25M -23M -75M -20M -19M -17M -51M -14M -12M -23M -10M
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0 0 0
incomeTaxExpense 0 0 55 000 0 0 -15 276 56 000 -25 000 -1M -1M 25 000 -564 000 0 3000 0
netIncome -25M -32M -70M -16M -25M -23M -76M -20M -19M -15M -52M -13M -12M -23M -10M
netIncomeRatio 0 0 0 0 0 0 0 0 0 0
eps -482.25 -863.46 -2.44 -0.56 -0.86 -0.83 -2.87 -0.71 -0.76 -0.62 -2.1 -0.53 -0.49 -1.87 -40.17
epsdiluted -482.25 -863.46 -0.56 -0.86 -0.83 -0.71 -0.76 -0.62 -0.53 -0.49
weightedAverageShsOut 40M 28M 29M 29M 29M 28M 26M 28M 25M 25M 24M 24M 24M 24M 24M
weightedAverageShsOutDil 40M 28M 29M 29M 29M 28M 26M 28M 25M 25M 24M 24M 24M 24M 24M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-27 2024-03-25 2023-03-29 2022-03-30 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 5M 6M 2M 0 -74 925
ebit -75M -81M -53M -23M -9M
nonOperatingIncomeExcludingInterest -6600 -6M -2M -62 000 647 000
netIncomeFromContinuingOperations -70M -76M -52M -23M -10M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -93 958 -76M -52M -23M -10M
epsDiluted -2.44 -2.87 -2.1 -1.87 -40.17

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-14 2025-08-13 2024-11-12 2024-08-12 2024-05-13 2023-11-13 2023-08-14 2023-05-15 2022-11-14 2022-08-15
acceptedDate 2025-11-14 07:13:30 2025-08-13 16:20:41 2025-03-27 07:30:28 2024-11-12 16:40:34 2024-08-12 16:31:10 2024-05-13 16:57:50 2024-03-25 16:15:50 2023-11-13 08:16:11 2023-08-14 08:16:01 2023-05-15 16:11:52 2023-03-29 17:04:43 2022-11-14 07:50:45 2022-08-15 08:00:54 2022-03-30 16:51:14 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 50M 221M 34M 31M 31M 9M 23M 32M 61M 27M 22M 22M 27M 54M 5M
shortTermInvestments 0 0 45M 58M 73M 90M 99M 103M 89M 92M 107M 120M 125M 113M 0
cashAndShortTermInvestments 50M 221M 79M 89M 104M 99M 122M 135M 150M 119M 129M 143M 152M 167M 5M
netReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 151M 2M 845 000 2M 7M 4M 250 000 567 000 2M 266 000 295 000 331 000 1M 240 000 38 000
totalCurrentAssets 201M 223M 80M 91M 111M 103M 124M 138M 152M 121M 131M 145M 153M 174M 5M
propertyPlantEquipmentNet 916 000 924 000 215 000 273 000 853 000 985 000 902 000 1M 1M 1M 1M 1M 2M 728 000 39 000
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 174 000 60 000 0 81 000 81 000 3M 2M 2M 2M 3M 3M 1M 731 000 302 000 0
totalNonCurrentAssets 1M 984 000 215 000 354 000 934 000 4M 3M 3M 3M 4M 4M 3M 2M 1M 39 000
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 202M 224M 80M 91M 112M 107M 127M 141M 156M 124M 135M 148M 156M 175M 5M
accountPayables 1M 8M 224 000 908 000 4M 3M 2M 4M 6M 5M 3M 5M 2M 1M 612 000
shortTermDebt 0 0 0 459 000 950 000 445 000 0 451 000 379 000 373 000 0 379 000 347 000 192 000 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 10M 7M 0 0 0 0 1M 0
otherCurrentLiabilities 21M 14M 319 000 9M 12M 12M 1M 439 000 583 000 6M 3M 3M 1M 168 000 970 000
totalCurrentLiabilities 22M 22M 4M 10M 17M 16M 18M 15M 13M 11M 8M 8M 4M 3M 2M
longTermDebt 747 000 792 000 0 81 000 206 000 329 000 0 358 000 476 000 591 000 0 800 000 862 000 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 70 000 70 000 70 000 69 999 70 000 70 000 69 000 70 000 71 000 -4M 13 000 13 000 0
totalNonCurrentLiabilities 747 000 792 000 70 000 151 000 276 000 398 999 325 000 428 000 545 000 661 000 776 000 813 000 875 000 395 000 16M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 417 000 540 000 681 000 329 000 675 000 809 000 855 000 964 000 1M 1M 1M 574 000 0
totalLiabilities 23M 22M 4M 10M 17M 16M 18M 15M 14M 11M 9M 9M 5M 3M 18M
preferredStock 2000 2000 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 3000 3000 3000 3000 3000 3000 3000 3000 3000 2000 2000 2000 2000 2000 0
retainedEarnings -142M -117M -233M -228M -211M -187M -163M -143M -123M -104M -88M -73M -59M -36M -13M
accumulatedOtherComprehensiveIncomeLoss 29 000 -24 000 105 000 0 -83 000 -33 000 237 000 -195 000 -223 000 -201 000 -466 000 -771 000 -785 000 -59 000 0
othertotalStockholdersEquity 322M 319M 308M 306M 278M 269M 266M 218M 213M 211M
totalStockholdersEquity 179M 202M 76M 80M 94M 91M 109M 126M 142M 113M 127M 139M 151M 172M -13M
totalEquity 179M 202M 76M 80M 94M 91M 109M 126M 142M 113M 127M 139M 151M 172M -13M
totalLiabilitiesAndStockholdersEquity 202M 224M 91M 112M 107M 141M 156M 124M 148M 156M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 202M 224M 80M 91M 112M 107M 127M 141M 156M 124M 135M 148M 156M 175M 5M
totalInvestments 0 0 45M 58M 73M 90M 99M 103M 89M 92M 107M 120M 0 113M 0
totalDebt 747 000 792 000 417 000 540 000 681 000 774 000 675 000 809 000 855 000 964 000 1M 1M 1M 574 000 0
netDebt -49M -220M -33M -31M -30M -8M -23M -31M -60M -26M -21M -21M -26M -54M -5M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-27 2024-03-25 2023-03-29 2022-03-30 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 0 0 0 0 0
prepaids 649 000 2M 2M 7M 65 000
totalPayables 224 000 2M 3M 1M 612 000
otherPayables 0 0 0 0 0
accruedExpenses 3M 14M 2M 790 000 192 000
capitalLeaseObligationsCurrent 417 000 420 000 385 000 192 000 0
capitalLeaseObligationsNonCurrent 0 255 000 705 000 382 000 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 309M 273M 215M 209M 63 000
otherTotalStockholdersEquity 0 0 0 0 -16M

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE AVTE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-14 2025-08-13 2024-11-12 2024-08-12 2024-05-13 2023-11-13 2023-08-14 2023-05-15 2022-11-14 2022-08-15
acceptedDate 2025-11-14 07:13:30 2025-08-13 16:20:41 2025-03-27 07:30:28 2024-11-12 16:40:34 2024-08-12 16:31:10 2024-05-13 16:57:50 2024-03-25 16:15:50 2023-11-13 08:16:11 2023-08-14 08:16:01 2023-05-15 16:11:52 2023-03-29 17:04:43 2022-11-14 07:50:45 2022-08-15 08:00:54 2022-03-30 16:51:14 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome -25M -68M -70M -16M -25M -23M -76M -20M -19M -17M -52M -14M -12M -23M -10M
depreciationAndAmortization -179 000 226 000 282 000 -2M 28 000 28 000 96 000 25 000 22 000 21 000 68 000 20 000 -4000 15 000 1000
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
stockBasedCompensation 4M 5M 11M 2M 4M 4M 12M 3M 3M 2M 5M 1M 2M 2M 58 000
changeInWorkingCapital 0 0 -11M 3M 1M -4M 10M 1M 2M 3M 8M 3M 6M -7M 974 000
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables -5M 5M -2M -3M 948 000 835 000 -164 000 -2M 773 000 2M 1M 2M 875 000 609 000 37 000
otherWorkingCapital 0 0 -9M 6M 193 000 -5M 10M 4M 892 000 1M 6M 399 000 0 -7M 937 000
otherNonCashItems -1M 26M -2M -3M -692 000 3M -3M -808 000 -639 000 -671 000 -910 000 -292 000 -11M 16 000 719 000
netCashProvidedByOperatingActivities -22M -37M -71M -16M -20M -24M -57M -16M -15M -11M -39M -10M -15M -27M -8M
investmentsInPropertyPlantAndEquipment -57 000 -136 000 0 0 0 0 -142 000 -32 000 -30 000 -16 000 -195 000 -33 000 -158 000 -181 000 0
acquisitionsNet 0 0 0 0 0 0 0 13 098 -4013 0 -7121 0 0 0 0
purchasesOfInvestments -149M 0 -20M -5M 0 -15M -124M -48M -33M -16M -148M -26M -72M -113M 0
salesMaturitiesOfInvestments 0 -13M 76M 21M 18M 24M 136M 35M 37M 31M 155M 30M 60M 0 0
otherInvestingActivites -59 000 0 0 0 9M -13 098 4013 0 0 0
netCashUsedForInvestingActivites -149M -13M 16M 18M 9M -13M 4M 15M 5M -12M
debtRepayment 0 0 0 0 0 0 0 0 0 0
commonStockIssued 0 0 -1M 24M 471 000 20 000 45M 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 191M 22 000 24M -233 000 -75 000 0 223 000 37 000 2000
netCashUsedProvidedByFinancingActivities 0 191M 22 000 24M 471 000 20 000 45M 223 000 37 000 2000
effectOfForexChangesOnCash -4000 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash -171M 177M 10M 46 000 22M -14M 1M -29M 34M 4M -32M -5M -680 000 50M 1M
cashAtEndOfPeriod 50M 221M 34M 31M 31M 9M 23M 32M 61M 27M 22M 22M 27M 54M 5M
cashAtBeginningOfPeriod 221M 44M 23M 31M 9M 23M 22M 61M 27M 22M 54M 27M 28M 5M 4M
operatingCashFlow -22M -37M -71M -16M -20M -24M -57M -16M -15M -11M -39M -10M -15M -27M -8M
capitalExpenditure -57 000 -136 000 0 0 0 0 -142 000 -32 000 -30 000 -16 000 -195 000 -33 000 -158 000 -181 000 0
freeCashFlow -22M -37M -71M -16M -20M -24M -57M -16M -15M -11M -39M -10M -15M -28M -8M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-27 2024-03-25 2023-03-29 2022-03-30 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 7121 -113 253 0
netCashProvidedByInvestingActivities 56M 12M 7M -113M 0
netDebtIssuance 0 0 0 0 3M
longTermNetDebtIssuance 0 0 0 0 3M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 24M 45M 0 190M 0
netCommonStockIssuance 24M 45M 0 127M 0
commonStockIssuance 24M 45M 150 000 127M 6M
netPreferredStockIssuance 0 1M 0 64M 6M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 1M 1M 396 000 0 6M
netCashProvidedByFinancingActivities 25M 46M 396 000 190M 9M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

SEC forms

Show financial reports only

SEC form 8
2026-01-05 12:17 ET
Aerovate Therapeutics, Inc. published news for 2025 q4
SEC form 8
2026-01-05 12:17 ET
Aerovate Therapeutics, Inc. published news for 2025 q4
SEC form 10
2025-11-14 07:13 ET
Aerovate Therapeutics, Inc. reported for 2025 q3
SEC form 8
2025-11-14 07:00 ET
Aerovate Therapeutics, Inc. published news for 2025 q3
SEC form 8
2025-11-14 07:00 ET
Aerovate Therapeutics, Inc. published news for 2025 q3
SEC form 8
2025-11-14 07:00 ET
Aerovate Therapeutics, Inc. published news for 2025 q3
SEC form 8
2025-11-14 07:00 ET
Aerovate Therapeutics, Inc. published news for 2025 q3
SEC form 10
2025-08-13 20:20 ET
Aerovate Therapeutics, Inc. reported for 2025 q2
SEC form 8
2025-08-13 20:14 ET
Aerovate Therapeutics, Inc. published news for 2025 q2
SEC form 8
2025-08-13 20:14 ET
Aerovate Therapeutics, Inc. published news for 2025 q2
SEC form 8
2025-04-29 20:05 ET
Aerovate Therapeutics, Inc. published news for 2025 q1
SEC form 8
2025-04-29 20:05 ET
Aerovate Therapeutics, Inc. published news for 2025 q1
SEC form 10
2025-04-25 20:30 ET
Aerovate Therapeutics, Inc. reported for 2025 q1
SEC form 10
2025-04-25 00:00 ET
Aerovate Therapeutics, Inc. reported for 2025 q1
SEC form 8
2025-04-09 20:09 ET
Aerovate Therapeutics, Inc. published news for 2025 q1
SEC form 8
2025-04-09 20:09 ET
Aerovate Therapeutics, Inc. published news for 2025 q1
SEC form 8
2025-04-07 12:39 ET
Aerovate Therapeutics, Inc. published news for 2025 q1
SEC form 8
2025-04-07 12:39 ET
Aerovate Therapeutics, Inc. published news for 2025 q1
SEC form 10
2025-03-27 07:30 ET
Aerovate Therapeutics, Inc. reported for 2024 q4
SEC form 10
2025-03-27 00:00 ET
Aerovate Therapeutics, Inc. reported for 2024 q4
SEC form 10
2024-11-12 16:40 ET
Aerovate Therapeutics, Inc. reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Aerovate Therapeutics, Inc. reported for 2024 q3
SEC form 10
2024-08-12 16:31 ET
Aerovate Therapeutics, Inc. reported for 2024 q2
SEC form 10
2024-08-12 00:00 ET
Aerovate Therapeutics, Inc. reported for 2024 q2
SEC form 10
2024-05-13 16:57 ET
Aerovate Therapeutics, Inc. reported for 2024 q1
SEC form 8
2024-05-13 16:39 ET
Aerovate Therapeutics, Inc. published news for 2024 q1
SEC form 8
2024-05-13 16:39 ET
Aerovate Therapeutics, Inc. reported for 2024 q1
SEC form 10
2024-05-13 00:00 ET
Aerovate Therapeutics, Inc. reported for 2024 q1
SEC form 10
2024-03-25 16:15 ET
Aerovate Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-03-25 16:12 ET
Aerovate Therapeutics, Inc. published news for 2023 q4
SEC form 8
2024-03-25 16:12 ET
Aerovate Therapeutics, Inc. reported for 2023 q4
SEC form 10
2024-03-25 00:00 ET
Aerovate Therapeutics, Inc. reported for 2023 q4
SEC form 10
2023-11-13 08:16 ET
Aerovate Therapeutics, Inc. reported for 2023 q3
SEC form 8
2023-11-13 08:03 ET
Aerovate Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-11-13 00:00 ET
Aerovate Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-08-14 08:16 ET
Aerovate Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-08-14 08:10 ET
Aerovate Therapeutics, Inc. reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Aerovate Therapeutics, Inc. reported for 2023 q2
SEC form 8
2023-08-14 00:00 ET
Aerovate Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-07-11 17:04 ET
Aerovate Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-07-11 17:03 ET
Aerovate Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-06-21 17:14 ET
Aerovate Therapeutics, Inc. published news for 2023 q1
SEC form 10
2023-05-15 16:11 ET
Aerovate Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-05-15 16:08 ET
Aerovate Therapeutics, Inc. reported for 2023 q1
SEC form 8
2023-05-15 00:00 ET
Aerovate Therapeutics, Inc. reported for 2023 q1
SEC form 10
2023-05-15 00:00 ET
Aerovate Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-04-19 16:31 ET
Aerovate Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-04-05 16:32 ET
Aerovate Therapeutics, Inc. published news for 2023 q1
SEC form 10
2023-03-29 17:04 ET
Aerovate Therapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-29 16:52 ET
Aerovate Therapeutics, Inc. reported for 2022 q4
SEC form 8
2023-03-29 00:00 ET
Aerovate Therapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-29 00:00 ET
Aerovate Therapeutics, Inc. reported for 2022 q4
SEC form 10
2022-11-14 00:00 ET
Aerovate Therapeutics, Inc. reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Aerovate Therapeutics, Inc. reported for 2022 q3
SEC form 8
2022-08-15 00:00 ET
Aerovate Therapeutics, Inc. reported for 2022 q2
SEC form 10
2022-08-15 00:00 ET
Aerovate Therapeutics, Inc. reported for 2022 q2
SEC form 8
2022-05-16 00:00 ET
Aerovate Therapeutics, Inc. reported for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Aerovate Therapeutics, Inc. reported for 2022 q1
SEC form 8
2022-03-30 00:00 ET
Aerovate Therapeutics, Inc. published news for 2021 q4
SEC form 10
2022-03-30 00:00 ET
Aerovate Therapeutics, Inc. published news for 2021 q4
SEC form 8
2021-11-15 00:00 ET
Aerovate Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Aerovate Therapeutics, Inc. published news for 2021 q3
SEC form 8
2021-08-16 00:00 ET
Aerovate Therapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-16 00:00 ET
Aerovate Therapeutics, Inc. published news for 2021 q2